Last reviewed · How we verify

NCT06629493

Feasibility and Effects of Activity Trackers Among Alcohol Users Receiving In-patient Treatment for Alcohol Use Disorder

Completed NA Last updated 22 September 2025
What this trial tests

NA trial testing Fitbit Versa 3 in Substance-Related Disorders in 90 participants. Completed in 2 July 2025.

Timeline
4 April 2022
Primary endpoint
1 July 2025
2 July 2025

Quick facts

Lead sponsorUniversity of Oviedo
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment90
Start date4 April 2022
Primary completion1 July 2025
Estimated completion2 July 2025
Sites1 location across Spain

Drugs / interventions tested

Conditions studied

Sponsor

University of Oviedo

Who can join

18 and older, any sex, with Substance-Related Disorders or Alcohol-Related Disorders. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main objective is to assess the feasibility and effectiveness of using activity trackers to increase physical activity and improve the emotional state of people receiving an in-patient treatment for alcohol use disorder

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Fitbit Versa 3

Trials testing the same drug.

Other recruiting trials for Substance-Related Disorders

Currently open trials in the same condition.

Other University of Oviedo trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06629493.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing